ASSESSMENT OF IFOSFAMIDE-INDUCED CARDIOVASCULAR DYSFUNCTION

异环磷酰胺引起的心血管功能障碍的评估

• 批准号: 3853059
• 负责人: F P OGNIBENE
• 金额: --
• 依托单位: CLINICAL CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3853059
• 关键词: arrhythmia; bone marrow transplantation; cardiogenic shock; cardiovascular disorder; congestive heart failure; dyspneas; hemodynamics; human subject; ifosfamide; image processing; immunoglobulin G; monoclonal antibody; neoplasm /cancer immunodiagnosis; neoplasm /cancer radionuclide diagnosis; neoplasm /cancer surgery; nuclear medicine; radioimmunoassay; radionuclide diagnosis; radionuclide imaging /scanning; radiotracer

Ifosfamide (IFF), an analog of cyclophosphamide, has not been previously reported to cause serious cardiac dysfunction. Some patients receiving high-dose IFF as induction therapy for autologous bone marrow transplantation have been observed to develop clinical evidence of congestive heart failure as manifested by dyspnea, hypoxemia, and weight gain. Serial radionuclide left ventricular ejection fractions and/or echocardiograms as well as complete hemodynamic parameters, as determined by pulmonary artery catheterizations, have been and will be followed in all patients admitted to the MICU with presumed IFF cardiac toxicity. All patients will be monitored for any arrhythmias and/or evidence of intractable cardiogenic shock. In addition, time course to cardiovascular recovery will also be monitored. Preliminary data in abstract form have been submitted to Clinical Research for publication. N. B. Data are being primarily collected for clinical reasons, however, and this should not be construed as an independent research project.

异环磷酰胺（IFF），环磷酰胺的类似物，以前没有 导致严重的心脏功能障碍 一些患者接受 大剂量异基因诱导因子对自体骨髓诱导治疗作用 已经观察到移植发展出临床证据， 充血性心力衰竭，表现为呼吸困难、低氧血症和体重 增益 连续放射性核素左心室射血分数和/或 超声心动图以及完整的血流动力学参数，如确定的 通过肺动脉插管，已经并将在所有 MICU收治的假定IFF心脏毒性患者。 所有 将监测患者的任何心律失常和/或 顽固性心源性休克 此外，心血管疾病的时间进程 恢复情况也将受到监测。 摘要形式的初步数据有 已提交临床研究以供发表。 N. B。然而，数据主要是出于临床原因收集的， 这不应被视为一个独立的研究项目。